Nuvectis Pharma

Q2 FY2026 EarningsQ2 FY2026 results missed consensus estimates across the bottom line: GAAP EPS was -$0.30 vs. -$0.26 expected, and net loss reached $7.0M vs. $6.4M anticipated. While revenue remained at $0 as expected for this clinical-stage firm, the variance was driven by higher-than-expected R&D spending (+30% YoY). However, the July follow-on offering raising $115M gross proceeds significantly strengthens the balance sheet, extending the cash runway into 1H 2029.